Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply

Core Insights - Eli Lilly is investing an additional $5.3 billion in a manufacturing plant in Lebanon, Indiana, to increase the supply of its weight loss drug Zepbound and diabetes treatment Mounjaro, bringing the total investment at the site to $9 billion, marking the largest manufacturing investment in the company's history [1][2] - The Lebanon site is expected to begin production by the end of 2026 and will ramp up operations through 2028, addressing the significant demand that has outpaced supply over the past year [1][2] - The plant will enhance Eli Lilly's capacity to manufacture tirzepatide, the active ingredient in Zepbound and Mounjaro, utilizing advanced technology and automation for efficiency and quality control [2] Investment and Employment - The new facility will employ approximately 900 staff members, including engineers, scientists, and lab technicians, once fully operational [2] - Since 2020, Eli Lilly has invested over $18 billion in building, expanding, and acquiring manufacturing plants in the U.S. and Europe [2] Production Capacity and Financial Outlook - Eli Lilly has multiple manufacturing sites either ramping up or under construction, including locations in Indiana, North Carolina, Ireland, and Germany, as well as a recently acquired site from Nexus Pharmaceuticals [3] - The company raised its full-year revenue outlook by $2 billion, reflecting confidence in increased production of Zepbound, Mounjaro, and other incretin drugs [3]